基于多特异性结合策略的抗病毒药物研究进展  

Recent advances of antiviral drugs based on multispecific binding strategy

作　　者：周洋 徐淑静 丁当 王硕 刘新泳[1] 展鹏[1] ZHOU Yang;XU Shu-jing;DING Dang;WANG Shuo;LIU Xin-yong;ZHAN Peng(Department of Medicinal Chemistry,Key Laboratory of Chemical Biology(Ministry of Education),School of Pharmaceutical Sciences,Shandong University,Jinan 250012,China)

机构地区：[1]山东大学药学院药物化学研究所,化学生物学教育部重点实验室,山东济南250012

出　　处：《药学学报》2023年第8期2203-2217,共15页Acta Pharmaceutica Sinica

基　　金：国家自然科学基金面上项目(82173677);山东省杰出青年基金(ZR2020JQ31).

摘　　要：为应对病毒耐药株的不断涌现和新型病毒感染性疾病的暴发,基于新策略的抗病毒药物研发成为重要且紧迫的研究课题。近年来,快速发展的多特异性结合策略已成为研究的焦点,并在抗病毒领域得到了广泛应用。本文从药物化学角度综述了多特异性结合策略在抗病毒领域的前沿进展,并对其面临的挑战及未来前景进行了讨论。To address the continuous emergence of drug-resistant strains of viruses and the outbreaks of novel virus infections,developing new antiviral drugs based on novel strategies has become an important and urgent research topic.In recent years,the rapidly developing multi-specific binding strategy has become a focus and been widely applied in antiviral.This review summarizes the recent progress of the multi-specific binding strategy in the antiviral field from the perspective of medicinal chemistry and discusses existing challenges as well as future opportunities for antiviral drug discovery.

关 键 词：病毒 多特异性结合策略 抗病毒药物 药物化学 药物设计 

分 类 号：R914[医药卫生—药物化学]